[go: up one dir, main page]

CL2008003284A1 - Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras. - Google Patents

Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras.

Info

Publication number
CL2008003284A1
CL2008003284A1 CL2008003284A CL2008003284A CL2008003284A1 CL 2008003284 A1 CL2008003284 A1 CL 2008003284A1 CL 2008003284 A CL2008003284 A CL 2008003284A CL 2008003284 A CL2008003284 A CL 2008003284A CL 2008003284 A1 CL2008003284 A1 CL 2008003284A1
Authority
CL
Chile
Prior art keywords
carboxyacyl
benzylamino
atherosclerosis
metabolic
treatment
Prior art date
Application number
CL2008003284A
Other languages
English (en)
Inventor
Yuki Iwaki
Ichiro Umemura
Hidetomo Imase
Toshio Kawanami
Muneto Mogi
Ken Yamada
Kayo Yasoshima
Hongb Qin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40343337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003284(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2008003284A1 publication Critical patent/CL2008003284A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos derivados de 4-bencilamino-1-carboxiacil-piperidina y sus sales farmacéuticamente aceptables; composiciones y combinaciones que los comprenden y suuso en el tratamiento de enfermedades metabólicas, cardiovasculares y aterosclerosis.
CL2008003284A 2007-11-05 2008-11-04 Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras. CL2008003284A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98545607P 2007-11-05 2007-11-05

Publications (1)

Publication Number Publication Date
CL2008003284A1 true CL2008003284A1 (es) 2009-05-15

Family

ID=40343337

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003284A CL2008003284A1 (es) 2007-11-05 2008-11-04 Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras.

Country Status (24)

Country Link
US (3) US8193349B2 (es)
EP (2) EP2207775B1 (es)
JP (1) JP5555635B2 (es)
KR (1) KR101564793B1 (es)
CN (1) CN101910150B (es)
AR (1) AR069165A1 (es)
AT (1) ATE550333T1 (es)
AU (1) AU2008324243B2 (es)
BR (1) BRPI0819223A2 (es)
CA (1) CA2704633C (es)
CL (1) CL2008003284A1 (es)
CY (1) CY1112706T1 (es)
DK (1) DK2207775T3 (es)
EA (1) EA022912B1 (es)
ES (2) ES2381518T3 (es)
HR (1) HRP20120476T1 (es)
JO (1) JO2732B1 (es)
MX (1) MX2010004929A (es)
PE (1) PE20090982A1 (es)
PL (2) PL2207775T3 (es)
PT (2) PT2463282E (es)
SI (1) SI2207775T1 (es)
TW (1) TWI426910B (es)
WO (1) WO2009059943A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101878199B (zh) 2007-12-03 2013-09-18 诺瓦提斯公司 用于治疗例如高血脂或动脉硬化疾病的作为cetp抑制剂的1，2-二取代的-4-苄基氨基-吡咯烷衍生物
UY32717A (es) 2009-06-17 2011-01-31 Vertex Pharma Inhibidores de la replicación de virus de la gripe
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
WO2012075381A1 (en) 2010-12-03 2012-06-07 Epizyme, Inc. Substituted purine and 7 - deazapurine compounds as modulators of epigenetic enzymes
WO2012101142A1 (en) 2011-01-26 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for assessing a subject's risk of having a cardiovascular disease.
ES2804528T3 (es) * 2011-07-05 2021-02-08 Vertex Pharma Procesos y productos intermedios para la producción de azaindoles
KR20190025737A (ko) * 2011-07-08 2019-03-11 노파르티스 아게 높은 트리글리세리드 대상체에서의 아테롬성동맥경화증의 치료 방법
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
HUE038570T2 (hu) 2011-11-14 2018-10-29 Regeneron Pharma Készítmények és eljárások izomtömeg és izomerõ növelésére GDF8 és/vagy aktivin A specifikus antagonizálásával
US10538475B2 (en) 2012-05-25 2020-01-21 Nutech Ventures Amphiphilic cyclobutenes and cylobutanes
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
AU2014293386B2 (en) 2013-07-25 2016-11-17 Novartis Ag Cyclic polypeptides for the treatment of heart failure
JP2016527249A (ja) 2013-07-25 2016-09-08 ノバルティス アーゲー 合成アペリンポリペプチドのバイオコンジュゲート
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
LT3421468T (lt) 2013-11-13 2021-01-11 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitorių paruošimo būdai
BR112017014194A2 (pt) 2015-01-23 2018-01-09 Novartis Ag conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada
CN104788482B (zh) * 2015-01-23 2016-09-14 沧州普瑞东方科技有限公司 一种制备2-氨基嘧啶-5-硼酸频那醇酯的方法
CN107771081A (zh) 2015-04-15 2018-03-06 瑞泽恩制药公司 用gdf8抑制剂增加力量和功能的方法
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
MA52417A (fr) 2018-03-01 2021-01-06 Regeneron Pharma Procédés de modification de composition corporelle

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
TW313568B (es) 1994-12-20 1997-08-21 Hoffmann La Roche
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
CA2345103C (en) 1998-09-25 2011-04-26 Monsanto Company (r)-chiral halogenated 1-substitutedamino-(n+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity
AUPP818099A0 (en) 1999-01-14 1999-02-11 Fujisawa Pharmaceutical Co., Ltd. New n-containing heterocyclic compounds
US6458849B1 (en) * 1999-09-23 2002-10-01 G.D. Searle & Co. use of substituted N,N-disubstituted mercapto amino compounds for inhibiting cholesteryl ester transfer protein activity
WO2001098344A2 (en) 2000-06-16 2001-12-27 Curis, Inc. Angiogenesis-modulating compositions and uses
GB0021885D0 (en) 2000-09-06 2000-10-18 Fujisawa Pharmaceutical Co New use
US7109204B2 (en) 2001-08-01 2006-09-19 Merck & Co., Inc. Tyrosine kinase inhibitors
ES2377318T3 (es) 2002-09-06 2012-03-26 Cerulean Pharma Inc. Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos
US7820682B2 (en) * 2002-10-03 2010-10-26 Ono Pharmaceutical Co., Ltd. LPA receptor antagonist
JPWO2004101529A1 (ja) 2003-05-19 2006-07-13 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
JP2007507481A (ja) * 2003-09-30 2007-03-29 ファイザー・プロダクツ・インク Ｃｅｔｐ阻害薬及びその代謝産物
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
ES2326326T3 (es) 2004-03-26 2009-10-07 Eli Lilly And Company Compuestos y procedimientos para tratar la dislipidemia.
MY139887A (en) 2004-04-02 2009-11-30 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same.
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
US20060270675A1 (en) * 2005-03-10 2006-11-30 Groneberg Robert D Inhibitors of cholesterol ester transfer protein
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
JP4258499B2 (ja) * 2005-07-25 2009-04-30 ヤマハ株式会社 吹奏電子楽器の音源制御装置とプログラム
US20070203183A1 (en) 2006-01-13 2007-08-30 Schering Corporation Diaryl piperidines as CB1 modulators
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
WO2007107843A1 (en) 2006-03-22 2007-09-27 Pfizer Products Inc. Methods of treatment with cetp inhibitors
UY30244A1 (es) * 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
EP2049517B1 (en) 2006-07-20 2013-11-27 Novartis AG Amino-piperidine derivatives as cetp inhibitors
JP4834699B2 (ja) 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
JP4846769B2 (ja) 2007-07-30 2011-12-28 田辺三菱製薬株式会社 医薬組成物
CN101878199B (zh) 2007-12-03 2013-09-18 诺瓦提斯公司 用于治疗例如高血脂或动脉硬化疾病的作为cetp抑制剂的1，2-二取代的-4-苄基氨基-吡咯烷衍生物
PT2231636E (pt) 2007-12-07 2012-01-02 Novartis Ag Derivados de pirazole e a sua utilização a título de inibidores de quinases dependentes de ciclina

Also Published As

Publication number Publication date
JO2732B1 (en) 2013-09-15
AU2008324243B2 (en) 2012-03-08
AU2008324243A1 (en) 2009-05-14
US8193349B2 (en) 2012-06-05
EP2207775B1 (en) 2012-03-21
US20120208816A1 (en) 2012-08-16
US8440682B2 (en) 2013-05-14
EA201000750A1 (ru) 2010-12-30
EP2463282B1 (en) 2013-08-07
US20090118287A1 (en) 2009-05-07
TW200924779A (en) 2009-06-16
CN101910150B (zh) 2013-09-18
CN101910150A (zh) 2010-12-08
EA022912B1 (ru) 2016-03-31
EP2463282A1 (en) 2012-06-13
CY1112706T1 (el) 2016-02-10
PL2207775T3 (pl) 2012-08-31
ATE550333T1 (de) 2012-04-15
PT2463282E (pt) 2013-11-11
PT2207775E (pt) 2012-05-11
KR20100094986A (ko) 2010-08-27
AR069165A1 (es) 2010-01-06
CA2704633C (en) 2015-10-20
TWI426910B (zh) 2014-02-21
ES2381518T3 (es) 2012-05-29
JP5555635B2 (ja) 2014-07-23
BRPI0819223A2 (pt) 2020-08-18
KR101564793B1 (ko) 2015-10-30
CA2704633A1 (en) 2009-05-14
PL2463282T3 (pl) 2014-01-31
HK1168096A1 (en) 2012-12-21
EP2207775A1 (en) 2010-07-21
PE20090982A1 (es) 2009-08-13
HRP20120476T1 (hr) 2012-06-30
US8420641B2 (en) 2013-04-16
ES2434417T3 (es) 2013-12-16
JP2011503026A (ja) 2011-01-27
WO2009059943A1 (en) 2009-05-14
MX2010004929A (es) 2010-05-27
SI2207775T1 (sl) 2012-05-31
US20120264773A1 (en) 2012-10-18
DK2207775T3 (da) 2012-06-18

Similar Documents

Publication Publication Date Title
CL2008003284A1 (es) Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras.
CR11857A (es) Compuestos pirazolicos 436
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
AR062875A1 (es) Compuestos de n- metilaminometil isoindol y composiciones que los comprenden y metodos para utilizarlos
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
UY32203A (es) Amino pirimidinas y su uso en terapia
CL2009000316A1 (es) Compuestos derivados de urea de benzomorfanos y sus sales, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de trastornos metabolicos.
DOP2010000259A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
UY32649A (es) "sales de 4-(dimetilamino)butil 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato"
UY32793A (es) Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
UY30759A1 (es) Compuestos quimicos
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
DOP2011000203A (es) Derivados de pirimidin indol para el tratamiento de cancer
UY33921A (es) Oxazinopteridinas y oxazinoptiridinonas n-sustituidas
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
UY31860A (es) Piridinas de tiazolo como inhibidoras de la adn girasa
UY31141A1 (es) Compuestos de piperidina y sus usos
SV2010003752A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas
UY31839A (es) Compuestos
AR063027A1 (es) Derivados de sulfonamida